rs41298442

Variant summary

Our verdict is Uncertain significance. Variant got 3 ACMG points: 5P and 2B. PM1PM2PP5BP4BS1_Supporting

The NM_000161.3(GCH1):​c.671A>G​(p.Lys224Arg) variant causes a missense change. The variant allele was found at a frequency of 0.000375 in 1,614,128 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00039 ( 0 hom., cov: 33)
Exomes 𝑓: 0.00037 ( 0 hom. )

Consequence

GCH1
NM_000161.3 missense

Scores

2
7
10

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:12U:5

Conservation

PhyloP100: 4.22
Variant links:
Genes affected
GCH1 (HGNC:4193): (GTP cyclohydrolase 1) This gene encodes a member of the GTP cyclohydrolase family. The encoded protein is the first and rate-limiting enzyme in tetrahydrobiopterin (BH4) biosynthesis, catalyzing the conversion of GTP into 7,8-dihydroneopterin triphosphate. BH4 is an essential cofactor required by aromatic amino acid hydroxylases as well as nitric oxide synthases. Mutations in this gene are associated with malignant hyperphenylalaninemia and dopa-responsive dystonia. Several alternatively spliced transcript variants encoding different isoforms have been described; however, not all variants give rise to a functional enzyme. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 3 ACMG points.

PM1
In a chain GTP cyclohydrolase 1 (size 249) in uniprot entity GCH1_HUMAN there are 25 pathogenic changes around while only 3 benign (89%) in NM_000161.3
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 14-54844099-T-C is Pathogenic according to our data. Variant chr14-54844099-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 9283.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=4, Uncertain_significance=5, Pathogenic=4}. Variant chr14-54844099-T-C is described in Lovd as [Pathogenic].
BP4
Computational evidence support a benign effect (MetaRNN=0.064124316). . Strength limited to SUPPORTING due to the PP5.
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.000394 (60/152344) while in subpopulation AMR AF= 0.00163 (25/15304). AF 95% confidence interval is 0.00113. There are 0 homozygotes in gnomad4. There are 30 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck. Existence of Clinvar submissions makes me limit the strength of this signal to Supporting

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
GCH1NM_000161.3 linkc.671A>G p.Lys224Arg missense_variant Exon 6 of 6 ENST00000491895.7 NP_000152.1 P30793-1A0A024R642

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
GCH1ENST00000491895.7 linkc.671A>G p.Lys224Arg missense_variant Exon 6 of 6 1 NM_000161.3 ENSP00000419045.2 P30793-1

Frequencies

GnomAD3 genomes
AF:
0.000394
AC:
60
AN:
152226
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00164
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.0000941
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000470
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000386
AC:
96
AN:
248968
Hom.:
0
AF XY:
0.000386
AC XY:
52
AN XY:
134764
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000896
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.0000327
Gnomad FIN exome
AF:
0.0000462
Gnomad NFE exome
AF:
0.000521
Gnomad OTH exome
AF:
0.000817
GnomAD4 exome
AF:
0.000374
AC:
546
AN:
1461784
Hom.:
0
Cov.:
31
AF XY:
0.000375
AC XY:
273
AN XY:
727198
show subpopulations
Gnomad4 AFR exome
AF:
0.0000597
Gnomad4 AMR exome
AF:
0.000760
Gnomad4 ASJ exome
AF:
0.0000765
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.0000187
Gnomad4 NFE exome
AF:
0.000435
Gnomad4 OTH exome
AF:
0.000364
GnomAD4 genome
AF:
0.000394
AC:
60
AN:
152344
Hom.:
0
Cov.:
33
AF XY:
0.000403
AC XY:
30
AN XY:
74502
show subpopulations
Gnomad4 AFR
AF:
0.0000481
Gnomad4 AMR
AF:
0.00163
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.0000941
Gnomad4 NFE
AF:
0.000470
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000400
Hom.:
0
Bravo
AF:
0.000351
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.000519
AC:
2
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000233
AC:
2
ExAC
AF:
0.000362
AC:
44
EpiCase
AF:
0.000654
EpiControl
AF:
0.000830

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:12Uncertain:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Dystonia 5 Pathogenic:3Uncertain:1
Feb 09, 2022
Institute of Human Genetics, University of Leipzig Medical Center
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Oct 22, 2002
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

-
Laboratory Cellgenetics, GMDL Cellgenetics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The following ACMG criteria were applied in classifying this variant: PS4, PM2, PP1, PP2, PP5. -

Nov 21, 2018
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Pathogenic:1Uncertain:3
Dec 19, 2024
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Identified as a single heterozygous variant in patients with childhood or adult-onset dopa-responsive dystonia or adult-onset parkinsonism referred for genetic testing at GeneDx and in published literature, and also incidentally detected in an asymptomatic family member with low urinary neopterin levels (PMID: 23430498, 15303002, 24993959, 25497597, 12391354, 37165102, 38214203); Reported as a heterozygous variant in unrelated patients with dystonia whose asymptomatic relatives also harbored the variant (PMID: 36233161, 34890878); Observed with second GCH1 variant on the opposite allele (in trans) in a patient with gait abnormalities, wrist rigidity, dystonic posturing in the arm, curling and cramping of toes, and bradykinesia, as well as postload elevation in phenylalanine after phenylalanine loading (PMID: 35083481); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 17044972, 33152132, 34497580, 20981092, 12391354, 15303002, 8852666, 25497597, 24993959, 10984668, 19332422, 18044725, 9667588, 29471552, 30894892, 30314816, 27313105, 31019283, 34426522, 35893043, 36833190, 35747429, 36628429, 34674384, 23942198, 37895316, 38214203, 37165102, 34890878, 23430498, 35083481, 36233161) -

Apr 15, 2022
Revvity Omics, Revvity
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 15, 2021
Athena Diagnostics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant associates with disease in multiple families presenting with dopa-responsive dystonia (DRD). The GCH1 gene is reported to exhibit gender-related incomplete penetrance of disease. Consistent with this variability, this variant has been reported in individuals ranging in presentation from severe DRD, to adult-onset parkinsonism, to asymptomatic. -

Apr 01, 2024
CeGaT Center for Human Genetics Tuebingen
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

GTP cyclohydrolase I deficiency Pathogenic:2
Nov 05, 2021
Mendelics
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Mar 11, 2023
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Variant summary: GCH1 c.671A>G (p.Lys224Arg) results in a conservative amino acid change located in the GTP cyclohydrolase I domain (IPR020602) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00039 in 248968 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in GCH1 causing GTP Cyclohydrolase I Deficiency (0.00039 vs 0.0011), allowing no conclusion about variant significance. In a cross-sectional review, c.671A>G has been reported in the literature as a compound heterozygous genotype in individuals with autosomal recessive DOPA responsive dystonia (DRD) and in individuals with autosomal dominant features of athetoid cerebral palsy, GTP-CH deficiency, DRD, Parkinson disease (PD) (example, PMID: 19332422, 8852666, 9667588, 12391354, 18044725, 23942198, 17044972, 30314816). However, due to the presence in control cohorts, the possibility of reduced penetrance cannot be excluded. These data indicate that the variant is very likely to be associated with disease. To our knowledge, no variant specific experimental evidence demonstrating an impact on protein function has been reported. Nine clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (P/LP, n=5; VUS, n=4). Based on the evidence outlined above, the variant was classified as pathogenic. -

Dystonia 5;CN305333:GTP cyclohydrolase I deficiency with hyperphenylalaninemia Pathogenic:2
Nov 01, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

- -

May 06, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

GTP cyclohydrolase I deficiency;C1851920:Dystonia 5 Pathogenic:1
Jan 25, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 224 of the GCH1 protein (p.Lys224Arg). This variant is present in population databases (rs41298442, gnomAD 0.08%). This missense change has been observed in individual(s) with autosomal dominant and autosomal recessive dopa-responsive dystonia (PMID: 9667588, 12391354, 15303002, 17044972, 18044725, 19332422, 25497597, 30314816, 35083481). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This missense change has also been observed in the heterozygous state in unaffected individuals, consistent with reduced penetrance (PMID: 19332422, 23430498). ClinVar contains an entry for this variant (Variation ID: 9283). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GCH1 protein function with a negative predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. -

Dopa-responsive dystonia Pathogenic:1
Jun 10, 2022
DASA
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.671A>G;p.(Lys224Arg) missense change has been observed in affected individual(s) and ClinVar contains an entry for this variant (PMID: 12391354; 9667588; 8852666) - PS4. The p.(Lys224Arg) was detected in trans with a Pathogenic variant (PM3: PMID: 9667588) - PM3. The variant co-segregated with disease in multiple affected family members (PMID: 12391354; 8852666) - PP1.andallele frequency is greater than expected for disorder - BS1. In summary, the currently available evidence indicates that the variant is Likely Pathogenic -

Dystonia, dopa-responsive, with or without hyperphenylalaninemia, autosomal recessive Pathogenic:1
Oct 22, 2002
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

GTP cyclohydrolase I deficiency with hyperphenylalaninemia Pathogenic:1
Jul 26, 2023
3billion
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.037%). Predicted Consequence/Location: Missense variant Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000009283 /PMID: 8852666). The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least one similarly affected unrelated individual (PMID: 9667588). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. -

Inborn genetic diseases Uncertain:1
Nov 18, 2021
Ambry Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The c.671A>G (p.K224R) alteration is located in exon 6 (coding exon 6) of the GCH1 gene. This alteration results from a A to G substitution at nucleotide position 671, causing the lysine (K) at amino acid position 224 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.077
BayesDel_addAF
Benign
-0.0090
T
BayesDel_noAF
Uncertain
0.13
CADD
Benign
21
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.71
D;D;D
Eigen
Benign
-0.36
Eigen_PC
Benign
-0.18
FATHMM_MKL
Uncertain
0.90
D
LIST_S2
Uncertain
0.89
.;D;.
M_CAP
Pathogenic
0.31
D
MetaRNN
Benign
0.064
T;T;T
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Benign
0.94
L;L;L
PrimateAI
Uncertain
0.61
T
PROVEAN
Benign
-1.4
.;N;N
REVEL
Uncertain
0.54
Sift
Benign
0.45
.;T;T
Sift4G
Benign
0.55
T;T;T
Polyphen
0.0
B;B;B
Vest4
0.62
MVP
0.99
MPC
0.86
ClinPred
0.037
T
GERP RS
2.3
Varity_R
0.16
gMVP
0.78

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs41298442; hg19: chr14-55310817; API